Hefei TG ImmunoPharma Co., Ltd

Phase Ia: Primary objectives: 1. Determine the MTD/RP2D of TGI-6 for injection in subjects with locally advanced or metastatic solid tumors. 2. Evaluate the safety profile of TGI-6 for injection in subjects with locally advanced or metastatic solid tumors. Secondary objectives: 1. Evaluate the PK characteristics of TGI-6 for injection in subjects with locally advanced or metastatic solid tumors. 2. Evaluate the preliminary anti-tumor activity of TGI-6 for injection in subjects with locally advanced or metastatic solid tumors. 3. Characterize the immunogenicity of TGI-6 for injection in subjects with locally advanced or metastatic solid tumors. Phase Ib: Primary objectives: Evaluate the anti-tumor activity of TGI-6 for injection in subjects with locally advanced or metastatic CRC or subjects with locally advanced or metastatic solid tumors confirmed to be B7-H6 positive. Secondary objectives: To evaluate other antitumor activity endpoints, overall safety profile, PK profile of TGI-6 for injection in subjects with locally advanced or metastatic CRC and locally advanced or metastatic solid tumors confirmed to be B7-H6 positive, and to characterize the immunogenicity of TGI-6 for injection in subjects with locally advanced or metastatic CRC or locally advanced or metastatic solid tumors confirmed to be B7-H6 positive.